On February 26, 2025 Neogap Therapeutics AB, a Swedish clinical-stage biotechnology company, reported that it has been awarded a USD 125,000 ScaleReady G-Rex Grant to optimise the development and manufacturing of its innovative personalised cancer immunotherapy, pTTL (Press release, Neogap Therapeutics, FEB 26, 2025, View Source;g-rex-grant-to-advance-personalised-cancer-immunotherapy,c4110383 [SID1234650547]). The funding supports Neogap’s efforts to further advance the manufacturing of their cell therapy product by developing a bioreactor process able to support large-scale manufacturing.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The G-Rex Grant is part of ScaleReady’s USD 20 million programme aimed at advancing Cell and Gene Therapy (CGT) development and manufacturing. With this funding, Neogap Therapeutics will optimise manufacturing for pTTL (personalised Tumour Trained Lymphocytes), an ATMP (Advanced Therapy Medicinal Product) that combines EpiTCer technology with the PIOR AI platform.
Designed to target neoantigens with precision, pTTL uses the patient’s immune cells to generate tumour-specific T cells. It is currently being evaluated in a Phase I/IIa clinical trial in patients with advanced colorectal cancer.
"We are very excited to have been selected for this significant grant from ScaleReady and look forward to incorporating the G-Rex platform into our pTTL manufacturing process," says Kristine Bylund, Head of Cell Therapy Production and Development at Neogap Therapeutics. "Our development team has already completed preliminary experiments, and this grant will allow us to continue the development of a robust and cost-effective bioreactor process required to meet our quality and safety standards for clinical production, bringing us closer to our goal of delivering personalised medicine to patients in need."
"We are fortunate to have the opportunity to help Neogap develop a cost-effective G-Rex centric manufacturing process to create personalised Tumour Trained Lymphocytes. Neogap’s novel approach has the potential to make a highly favorable impact on clinical outcomes for patients with advanced colorectal cancer and are grateful for the opportunity to participate," says John Wilson, CEO of Wilson Wolf and co-inventor of G-Rex.
About Neogap’s immunotherapy, pTTL
pTTL (personalised Tumour Trained Lymphocytes) is a cell-based immunotherapy that enhances the patient’s own T cells to fight cancer. The therapy combines advanced DNA analysis with T-cell expansion in a precision treatment for solid tumours. It is based on Neogap’s patented technologies, PIOR and EpiTCer. The goal is to provide patients with a tailored and innovative therapy that meets their specific needs.